Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

FILE - A Merck scientist conducts research on Feb. 28, 2013, in West Point, Pa. Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

FILE - A Merck scientist conducts research on Feb. 28, 2013, in West Point, Pa. (AP Photo/Matt Rourke, File) (Matt Rourke, Copyright 2017 The Associated Press. All ...

Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex workstation. The multi-year collaboration will see scientists and engineers ...

Scientists at Harvard Medical School and Boston University ... Fearns is the recipient of a sponsored research agreement with Merck & Co for work on polymerases of related viruses. Disclaimer: AAAS ...

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors. In this webinar, Ethan Shelkey and Aurita Menezes will highlight key aspects in the design of cell-based ...

Scientists and engineers will collaborate to develop and verify platform workflows utilizing the broad offering of automation-enabled assays from the Life Science business of Merck KGaA ...

Aims to revolutionize pharmaceutical manufacturing with focus on advanced aseptic processing technology.

Purdue University, in collaboration with Eli Lilly and Company and Merck & Co. Inc., announced Friday (Jan. 17 ... generation of skilled pharmaceutical manufacturing engineers and scientists. Through ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.